Results overview: Found 1 records in 0.02 seconds.
Research literature, 1 records found
Research literature 1 records found  
1.
21 p, 2.0 MB Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone / Michaelides, Michael (NIH) ; Levinstein, Marjorie (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; De Oliveira, Paulo (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Casajuana-Martin, Nil (Universitat Autònoma de Barcelona) ; Quiroz, Cesar (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Budinich, Reece (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Rais, Rana (Johns Hopkins School of Medicine) ; Rea, William (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Ventriglia, Emilya (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Llopart, Natàlia (Universitat de Barcelona) ; Casadó-Anguera, Verònica (Universitat de Barcelona) ; Moreno, Estefanía (University of Barcelona. Department of Biochemistry and Molecular Biomedicine) ; Walther, Donna (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Glatfelter, Grant (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Weinshenker, David ; Zarate, Carlos (NIMH) ; Casadó, Vicent (Universitat de Barcelona) ; Baumann, Michael (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica)) ; Pardo Carrasco, Leonardo (Universitat Autònoma de Barcelona) ; Ferré, Sergi (National Institute on Drug Abuse (Baltimore, Estats Units d'Amèrica))
(R,S)-methadone ((R,S)-MTD) is a racemic μ-opioid receptor (MOR) agonist comprised of (R)-MTD and (S)-MTD enantiomers used for the treatment of opioid use disorder (OUD) and pain. (R)-MTD is used as an OUD treatment, has high MOR potency, and is believed to mediate (R,S)-MTD's therapeutic efficacy. [...]
2023 - 10.21203/rs.3.rs-2644719/v1  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.